Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.78 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | CTSV | O60911 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HNF4A | P41235 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965404 | 0.89 | MCL1 (0.64) | MCL1MAOBPTGESNR4A2MAOA | |
| SCHEMBL31580821 | 0.89 | MCL1 (0.72) | MCL1MAOBNR4A2MAOACTSV | |
| SCHEMBL1519064 | 0.89 | MAOB (0.77) | MCL1MAOBNR4A2NR4A1NR4A3 | |
| SCHEMBL16320470 | 0.88 | MCL1 (1.00) | MCL1MAOBPTGESNR4A2NR4A1 | |
| SCHEMBL560607 | 0.88 | MAOB (0.81) | MCL1MAOBPTGESMAOALMNA | |
| SCHEMBL14770775 | 0.88 | MCL1 (0.62) | MCL1MAOBPTGESMAOACTSV | |
| SCHEMBL7161222 | 0.87 | MAOB (0.65) | MCL1MAOBNR4A2NR4A1NR4A3 | |
| SCHEMBL16704452 | 0.86 | MAOB (0.60) | MCL1MAOBMAOAALDH1A1 | |
| SCHEMBL13977571 | 0.86 | RXRA (0.61) | MCL1MAOBMAOAKMT2AALDH1A1 | |
| SCHEMBL14774262 | 0.86 | RAB9A (0.61) | MCL1MAOBMAOAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | claimed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | claimed |
| EP-2061453-B1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES SL (ES) | 2013-03-13 | — | — | EP | claimed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | claimed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | claimed |
| EP-2061453-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | Action Medicines, S.L. (ES) | 2009-05-27 | — | — | EP | claimed |
| EP-2056805-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | claimed |
| EP-2056804-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | claimed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | claimed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| EP-2710431-B1 | TONER | CANON KK (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | ACTION MEDICINES, S.L. (ES) | 2017-03-09 | — | — | US | disclosed |
| US-9511044-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9248114-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2016-02-02 | — | — | US | disclosed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | disclosed |
| US-9060966-B2 | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-06-23 | — | — | US | disclosed |
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-8889737-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2014-11-06 | — | — | US | disclosed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | disclosed |
| US-8574801-B2 | Toner | CANON KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8574801-B2 | Toner | CANON KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8541467-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2013-09-24 | — | — | US | disclosed |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-8436045-B2 | Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis | AmDerma Pharmaceuticals, LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130065174-A1 | TONER | CANON KABUSHIKI KAISHA (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20130065174-A1 | TONER | CANON KABUSHIKI KAISHA (JP) | 2013-03-14 | — | — | US | disclosed |
| EP-2061453-B1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES SL (ES) | 2013-03-13 | — | — | EP | disclosed |
| US-20120295190-A1 | TONER | CANON KABUSHIKI KAISHA (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120295190-A1 | TONER | CANON KABUSHIKI KAISHA (JP) | 2012-11-22 | — | — | US | disclosed |
| CN-102531905-A | Novel gentisic acid derivative 2-hydroxy-5-alkyl oxybenzoic acid esters, preparation method and novel application thereof | SICHUAN HUAFU BIOTECHNOLOGY CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101660-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | disclosed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | disclosed |
| CN-101648919-A | 3-substituted salicylamide compound, preparation method, medicinal composition and application thereof | INST MATERIA MEDICA CAMS | 2010-02-17 | — | — | CN | disclosed |
| EP-2061453-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | Action Medicines, S.L. (ES) | 2009-05-27 | — | — | EP | disclosed |
| EP-2056804-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | disclosed |
| EP-2056805-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | Action Medicines, S.L. (ES) | 2009-05-13 | — | — | EP | disclosed |
| EP-2054045-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | Action Medicines, S.L. (ES) | 2009-05-06 | — | — | EP | disclosed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | disclosed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | disclosed |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | disclosed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | disclosed |
| US-20080114060-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy with other drugs or photodynamic therapy | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | disclosed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020027-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| US-4355070-A | COLOR FORMER, DEVELOPER, HEAT FUSIBLE MATERIAL AND OIL ABSORPTIVE PIGMENT | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| US-4311758-A | INORGANIC PIGMENTS IN THE COLOR DEVELOPER LAYER | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1982-01-19 | — | — | US | disclosed |
| US-4236732-A | COLOR DEVELOPING LAYER CONTAINING PARTICLES OF A CHROMOGENIC MATERIAL, AN ACCEPTOR AND A HEAT FUSIBLE MATERIAL | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
| US-4228222-A | COLOR DEVELOPING LAYER INCLUDING WATER SOLUBLE RESIN AS BINDER | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1980-10-14 | — | — | US | disclosed |
| US-4168845-A | Heat-sensitive record material | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1979-09-25 | — | — | US | disclosed |
| US-3983292-A | Pressure sensitive recording papers | SANKO CHEMICAL COMPANY LTD. (JA) | 1976-09-28 | — | — | US | disclosed |
| US-3983292-A | Pressure sensitive recording papers | SANKO CHEMICAL COMPANY LTD. (JA) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ARSA, CYP8B1, EBP | MCL1 2983/4885MAOB 469/4885PTGES 2493/4885 |
| US-20080125486-A1 | sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy | STS, MPST, TST | MCL1 158/4885MAOB 4449/4885PTGES 3121/4885 |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | MCL1 1572/4885MAOB 278/4885PTGES 2789/4885 |
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | MCL1 1572/4885MAOB 278/4885PTGES 2789/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | MCL1 1572/4885MAOB 278/4885PTGES 2789/4885 |
| US-20130202580-A1 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis | CYP8B1, DERA, KRT18 | MCL1 3242/4885MAOB 489/4885PTGES 2900/4885 |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | CYP11B1, CYP11B2, MYLK | MCL1 2466/4885MAOB 102/4885PTGES 526/4885 |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | MCL1 1572/4885MAOB 278/4885PTGES 2789/4885 |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ALDH1A2, CRYAB, HSD17B14 | MCL1 4435/4885MAOB 139/4885PTGES 1450/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | MCL1 1572/4885MAOB 278/4885PTGES 2789/4885 |
| US-20080114060-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy with other drugs or photodynamic therapy | ALAD, ARSA, STS | MCL1 1455/4885MAOB 2552/4885PTGES 602/4885 |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | HMBS, HCLS1, CYP2S1 | MCL1 34/4885MAOB 1464/4885PTGES 4611/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | MCL1 3242/4885MAOB 489/4885PTGES 2900/4885 |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | CYP8B1, CYP26B1, UGT2B7 | MCL1 2904/4885MAOB 118/4885PTGES 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.